A dose-finding study of cannabidiol in dogs with idiopathic epilepsy

Epilepsy is currently reported to affect approximately 5% of the canine population; of that number approximately 30% of dogs are poorly controlled on routine anti-epileptic drugs (AEDs). Recent CBD research has demonstrated the anti-convulsive properties in both canine and human patients; however, to-date a dose finding study has not been performed in veterinary patients. In the second phase of this study, we’re looking at the dose chosen in the first phase over a period of 6 months to determine if this dose is effective in producing an adequate number of responders (50% or greater reduction in seizure frequency).

Once it has been verified that initial criteria have been met, dogs will come to CSU to have a neurologic examination, undergo an MRI and CSF tap, and have bloodwork performed, including AED levels, to rule out any obvious causes of epilepsy. At this visit we will also check a CBD level to ensure there’s no current CBD in the system. If a dog has already had an MRI and CSF tap performed recently it will not be necessary to repeat. After the MRI and CSF tap, you will go home with a 3-month supply of CBD oil to be given twice daily. You will be required to come to CSU at month 3 and month 6 so we can check bloodwork and perform an exam.

Out-of-state enrollments may be accepted on a case-by-case basis.